List of therapeutic monoclonal antibodies

This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

mab: whole monoclonal antibody
Fab: fragment, antigen-binding (one arm)
- F(ab')₂: fragment, antigen-binding, including hinge region (both arms)
- Fab': fragment, antigen-binding, including hinge region (one arm)
Variable fragments:
- scFv: single-chain variable fragment
- di-scFv: dimeric single-chain variable fragment
- sdAb: single-domain antibody
Bispecific monoclonal antibodies:
- 3funct: trifunctional antibody
- BiTE: bi-specific T-cell engager

This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA approved therapeutic monoclonal antibodies in the Monoclonal antibody therapy page.

Name	Trade name	Type	Source	Target	Approved	Use
3F8		mab	mouse	GD2 ganglioside		neuroblastoma
8H9[1]		mab	mouse	B7-H3		neuroblastoma, sarcoma, metastatic brain cancers
Abagovomab[2]		mab	mouse	CA-125 (imitation)		ovarian cancer
Abciximab	ReoPro	Fab	chimeric	CD41 (integrin alpha-IIb)	Y	platelet aggregation inhibitor
Abituzumab[3]		mab	humanized	CD51		cancer
Abrezekimab[4]		Fab	humanized	interleukin 13		?
Abrilumab		mab	human	integrin α4β7		inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab		mab	human	Clostridium difficile		Clostridium difficile colitis
Adalimumab	Humira	mab	human	TNF-α	Y	Rheumatoid arthritis, Crohn's disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hemolytic disease of the newborn
Adecatumumab[5]		mab	human	EpCAM		prostate and breast cancer
Atidortoxumab[6]		mab	human	Staphylococcus aureus alpha toxin		?
Aducanumab		mab	human	beta-amyloid		Alzheimer's disease
Afasevikumab[7]		mab	human	IL17A and IL17F		multiple sclerosis
Afelimomab		F(ab')₂	mouse	TNF-α		sepsis
Alacizumab pegol[8]		F(ab')₂	humanized	VEGFR2		cancer
Alemtuzumab[9]	Lemtrada, Campath	mab	humanized	CD52	Y	Multiple sclerosis
Alirocumab	Praluent	mab	human	PCSK9	Y	hypercholesterolemia
Altumomab pentetate	Hybri-ceaker	mab	mouse	CEA		colorectal cancer (diagnosis)
Amatuximab		mab	chimeric	mesothelin		cancer
Anatumomab mafenatox		Fab	mouse	TAG-72		non-small cell lung carcinoma
Andecaliximab		mab	chimeric	gelatinase B		gastric cancer or gastroesophageal junction adenocarcinoma
Anetumab ravtansine[3]		mab	human	MSLN		cancer
Anifrolumab		mab	human	interferon α/β receptor		systemic lupus erythematosus
Anrukinzumab[8] (= IMA-638)[10]		mab	humanized	IL-13		asthma
Apolizumab[11]		mab	humanized	HLA-DR ?		hematological cancers
Aprutumab ixadotin[12]		mab	human	FGFR2		?
Arcitumomab	CEA-Scan	Fab'	mouse	CEA		gastrointestinal cancers (diagnosis)
Ascrinvacumab		mab	human	activin receptor-like kinase 1		cancer
Aselizumab[13]		mab	humanized	L-selectin (CD62L)		severely injured patients
Atezolizumab[14]	Tecentriq	mab	humanized	PD-L1	Y	cancer
Atinumab[15]		mab	human	RTN4		?
Atorolimumab		mab	human	Rhesus factor		hemolytic disease of the newborn
Avelumab[7]	Bavencio	mab	human	PD-L1	Y	cancer
Azintuxizumab vedotin[16]		mab	chimeric/humanized	CD319		cancer
Bapineuzumab[17]		mab	humanized	beta amyloid		Alzheimer's disease
Basiliximab	Simulect	mab	chimeric	CD25 (α chain of IL-2 receptor)	Y	prevention of organ transplant rejections
Bavituximab[2]		mab	chimeric	phosphatidylserine		cancer, viral infections
BCD-100		?	human	PD-1		melanoma
Bectumomab	LymphoScan	Fab'	mouse	CD22		non-Hodgkin's lymphoma (detection)
Begelomab[18]		mab	mouse	DPP4		?
Belantamab mafodotin[4]		mab	humanized	BCMA		multiple myeloma
Belimumab	Benlysta	mab	human	BAFF	Y	systemic lupus erythematosus without renal or CNS involvement
Bemarituzumab[6]		mab	humanized	FGFR2		gastric cancer or gastroesophageal junction adenocarcinoma
Benralizumab	Fasenra	mab	humanized	CD125	Y	asthma
Berlimatoxumab[6]		mab	human	Staphylococcus aureus bi-component leukocidin		?
Bermekimab	Xilonix	mab	human	IL1A		colorectal cancer
Bersanlimab[4]		mab	human	ICAM-1		?
Bertilimumab[13]		mab	human	CCL11 (eotaxin-1)		severe allergic disorders
Besilesomab[19]	Scintimun	mab	mouse	CEA-related antigen		inflammatory lesions and metastases (detection)
Bevacizumab[9]	Avastin	mab	humanized	VEGF-A	Y	metastatic cancer, retinopathy of prematurity
Bezlotoxumab	Zinplava	mab	human	Clostridium difficile	Y	Clostridium difficile colitis
Biciromab	FibriScint	Fab'	mouse	fibrin II, beta chain		thromboembolism (diagnosis)
Bimagrumab[20]		mab	human	ACVR2B		myostatin inhibitor
Bimekizumab[21]		mab	humanized	IL 17A and IL 17F		ankylosing spondylitis, psoriasis
Birtamimab		mab	chimeric	serum amyloid A protein		amyloidosis
Bivatuzumab mertansine		mab	humanized	CD44 v6		squamous cell carcinoma
Bleselumab[7]		mab	human	CD40		organ transplant rejection
Blinatumomab	Blincyto	BiTE	mouse	CD19	Y	pre-B ALL (CD19+)
Blontuvetmab[22]	Blontress	mab	veterinary	CD20
Blosozumab[23]		mab	humanized	SOST		osteoporosis
Bococizumab		mab	humanized	neural apoptosis-regulated proteinase 1		dyslipidemia
Brazikumab[24]		mab	human	IL23		Crohn's disease
Brentuximab vedotin	Adcentris	mab	chimeric	CD30 (TNFRSF8)	Y	Hodgkin's lymphoma Anaplastic large-cell lymphoma
Briakinumab		mab	human	IL-12, IL-23		psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab	Siliq	mab	human	IL-17	Y	Plaque psoriasis
Brolucizumab[14]	Beovu	scFv	humanized	VEGFA	Y	wet age-related macular degeneration
Brontictuzumab[18]		mab	humanized	Notch 1		cancer
Burosumab[24]	Crysvita	mab	human	FGF 23	Y	X-linked hypophosphatemia
Cabiralizumab[22]		mab	humanized	CSF1R		metastatic pancreatic cancer
Camidanlumab tesirine[6]		mab	human	CD25		B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
Camrelizumab[12]		mab	humanized	PD-1		hepatocellular carcinoma
Canakinumab[25]	Ilaris	mab	human	IL-1	Y	Cryopyrin-associated periodic syndrome
Cantuzumab mertansine		mab	humanized	mucin CanAg		colorectal cancer etc.
Cantuzumab ravtansine[23]		mab	humanized	MUC1		cancers
Caplacizumab[26]	Cablivi	sdAb	humanized	VWF	Y	thrombotic thrombocytopenic purpura, thrombosis
Capromab pendetide	Prostascint	mab	mouse	prostatic carcinoma cells	Y	prostate cancer (detection)
Carlumab		mab	human	MCP-1		oncology/immune indications
Carotuximab[22]		mab	chimeric	endoglin		angiosarcoma
Catumaxomab[17]	Removab	3funct	rat/mouse hybrid	EpCAM, CD3	Y	ovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugate		mab	humanized	Lewis-Y antigen		cancer
Cedelizumab		mab	humanized	CD4		prevention of organ transplant rejections, treatment of autoimmune diseases
Cemiplimab	Libtayo	mab	human	PDCD1	Y	cutaneous squamous cell carcinoma
Cergutuzumab amunaleukin[7]		mab	humanized	IL2		cancer
Certolizumab pegol[5]	Cimzia	Fab'	humanized	TNF-α	Y	Crohn's disease, Rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis
Cetrelimab[4]		mab	human	PD-1		cancer
Cetuximab	Erbitux	mab	chimeric	EGFR	Y	metastatic colorectal cancer and head and neck cancer
Cibisatamab[4]		mab	humanized	CEACAM5		cancer
Cirmtuzumab		?	humanized	ROR1		chronic lymphocytic leukemia
Citatuzumab bogatox[27]		Fab	humanized	EpCAM		ovarian cancer and other solid tumors
Cixutumumab		mab	human	IGF-1 receptor (CD221)		solid tumors
Clazakizumab[28]		mab	humanized	IL6		Rheumatoid arthritis
Clenoliximab		mab	chimeric	CD4		Rheumatoid arthritis
Clivatuzumab tetraxetan	hPAM4-Cide	mab	humanized	MUC1		pancreatic cancer
Codrituzumab[3]		mab	humanized	glypican 3		cancer
Cofetuzumab pelidotin[6]		mab	humanized	PTK7		cancer
Coltuximab ravtansine[3]		mab	chimeric	CD19		cancer
Conatumumab[27]		mab	human	TRAIL-R2		cancer
Concizumab[20]		mab	humanized	TFPI		bleeding
Cosfroviximab[16]	ZMapp	mab	chimeric	ebolavirus glycoprotein		Ebola virus
Crenezumab		mab	humanized	1-40-β-amyloid		Alzheimer's disease
Crizanlizumab[12]	Adakveo	mab	humanized	selectin P	Y	sickle-cell disease
Crotedumab[22]		mab	human	GCGR		diabetes
CR6261		mab	human	Influenza A hemagglutinin		infectious disease/influenza A
Cusatuzumab[4]		mab	humanized	CD70		cancer
Dacetuzumab[8]		mab	humanized	CD40		hematologic cancers
Daclizumab	Zenapax	mab	humanized	CD25 (α chain of IL-2 receptor)	Y	prevention of organ transplant rejections, multiple sclerosis
Dalotuzumab		mab	humanized	IGF-1 receptor (CD221)		cancer etc.
Dapirolizumab pegol[21]		mab	humanized	CD154 (CD40L)		?
Daratumumab[29]	Darzalex	mab	human	CD38	Y	Multiple myeloma
Dectrekumab[14]		mab	human	IL-13		?
Demcizumab		mab	humanized	DLL4		cancer
Denintuzumab mafodotin[18]		mab	humanized	CD19		cancer
Denosumab[30]	Prolia	mab	human	RANKL	Y	osteoporosis, bone metastases etc.
Depatuxizumab mafodotin[24]		mab	chimeric/humanized	EGFR		glioblastoma
Derlotuximab biotin		mab	chimeric	histone complex		recurrent glioblastoma multiforme
Detumomab		mab	mouse	B-lymphoma cell		lymphoma
Dezamizumab[12]		mab	humanized	serum amyloid P component		?
Dinutuximab	Unituxin	mab	chimeric	GD2 ganglioside	Y	neuroblastoma
Diridavumab		mab	human	hemagglutinin		influenza A
Domagrozumab[22]		mab	humanized	GDF-8		Duchenne muscular dystrophy
Dorlimomab aritox[31]		F(ab')₂	mouse	?		?
Dostarlimab[32]		mab	humanized	PCDP1		cancer
Drozitumab		mab	human	DR5		cancer etc.
DS-8201		?	humanized	HER2		gastric or gastroesophageal junction adenocarcinoma
Duligotuzumab[33]		mab	humanized	ERBB3 (HER3)		testicular cancer
Dupilumab	Dupixent	mab	human	IL-4Rα	Y	atopic dermatitis, asthma, nasal polyps
Durvalumab	Imfinzi	mab	human	PD-L1	Y	cancer
Dusigitumab		mab	human	ILGF2		B-cell malignancies
Duvortuxizumab[16]		scFv	chimeric/humanized	CD19, CD3E		cancer
Ecromeximab[11]		mab	chimeric	GD3 ganglioside		malignant melanoma
Eculizumab[11]	Soliris	mab	humanized	C5	Y	paroxysmal nocturnal hemoglobinuria, atypical HUS
Edobacomab		mab	mouse	endotoxin		sepsis caused by Gram-negative bacteria
Edrecolomab	Panorex	mab	mouse	EpCAM		colorectal carcinoma
Efalizumab[34]	Raptiva	mab	humanized	LFA-1 (CD11a)		psoriasis (blocks T-cell migration)
Efungumab[2]	Mycograb	scFv	human	Hsp90		invasive Candida infection
Eldelumab		mab	human	interferon gamma-induced protein		Crohn's disease, ulcerative colitis
Elezanumab[12]		mab	human	RGMA		spinal cord injury and multiple sclerosis
Elgemtumab[14]		mab	human	ERBB3 (HER3)		cancer
Elotuzumab	Empliciti	mab	humanized	SLAMF7	Y	multiple myeloma
Elsilimomab		mab	mouse	IL-6		?
Emactuzumab[18]		mab	humanized	CSF1R		cancer
Emapalumab	Gamifant	mab	human	interferon gamma	Y	hemophagocytic lymphohistiocytosis
Emibetuzumab		mab	humanized	HHGFR		cancer
Emicizumab[7]	Hemlibra	mab	humanized	activated F9, F10	Y	haemophilia A
Enapotamab vedotin[4]		mab	human	AXL		cancer
Enavatuzumab		mab	humanized	TWEAK receptor		cancer etc.
Enfortumab vedotin		mab	human	nectin-4		urothelial cancer
Enlimomab pegol[35]		mab	mouse	ICAM-1 (CD54)		?
Enoblituzumab		mab	humanized	CD276		cancer
Enokizumab		mab	humanized	IL9		asthma
Enoticumab[33]		mab	human	DLL4		?
Ensituximab		mab	chimeric	5AC		cancer
Epitumomab cituxetan[36]		mab	mouse	episialin		?
Epratuzumab		mab	humanized	CD22		cancer, SLE
Eptinezumab		mab	humanized	calcitonin gene-related peptide		migraine
Erenumab[24]	Aimovig	mab	human	CGRP	Y	migraine
Erlizumab[37]		F(ab')₂	humanized	ITGB2 (CD18)		heart attack, stroke, traumatic shock
Ertumaxomab[17]	Rexomun	3funct	rat/mouse hybrid	HER2/neu, CD3	Y	breast cancer etc.
Etaracizumab	Abegrin	mab	humanized	integrin α_vβ₃	Y	melanoma, prostate cancer, ovarian cancer etc.
Etigilimab[4]		mab	humanized	TIGIT		?
Etrolizumab		mab	humanized	integrin β₇		inflammatory bowel disease
Evinacumab		mab	human	angiopoietin 3		dyslipidemia
Evolocumab[20]	Repatha	mab	human	PCSK9	Y	hypercholesterolemia
Exbivirumab[38]		mab	human	hepatitis B surface antigen		hepatitis B
Fanolesomab[39]	NeutroSpec	mab	mouse	CD15		appendicitis (diagnosis)
Faralimomab		mab	mouse	interferon receptor		?
Faricimab[4]		mab	humanized	VEGF-A and Ang-2		angiogenesis, ocular vascular diseases
Farletuzumab		mab	humanized	folate receptor 1		ovarian cancer
Fasinumab		mab	human	HNGF		acute sciatic pain
FBTA05[40][41]	Lymphomun	3funct	rat/mouse hybrid	CD20		chronic lymphocytic leukaemia
Felvizumab		mab	humanized	respiratory syncytial virus		respiratory syncytial virus infection
Fezakinumab[42][43]		mab	human	IL-22		Rheumatoid arthritis, psoriasis
Fibatuzumab[7]		mab	humanized	ephrin receptor A3		?
Ficlatuzumab		mab	humanized	HGF		cancer etc.
Figitumumab		mab	human	IGF-1 receptor (CD221)		adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[18]		mab	human	influenza A virus hemagglutinin		?
Flanvotumab		mab	human	TYRP1 (glycoprotein 75)		melanoma
Fletikumab		mab	human	IL 20		Rheumatoid arthritis
Flotetuzumab[4]		di-scFv	humanized	IL 3 receptor		hematological malignancies
Fontolizumab[11]	HuZAF	mab	humanized	IFN-γ		Crohn's disease etc.
Foralumab[44]		mab	human	CD3 epsilon		?
Foravirumab[27]		mab	human	rabies virus glycoprotein		rabies (prophylaxis)
Fremanezumab[12]	Ajovy	mab	humanized	calcitonin gene-related peptide alpha	Y	migraine and cluster headache
Fresolimumab		mab	human	TGF-β		idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Frovocimab[32]		mab	humanized	PCSK9		hypercholesterolemia
Frunevetmab[16]		mab	veterinary	NGF		?
Fulranumab		mab	human	NGF		pain
Futuximab[33]		mab	chimeric	EGFR		cancer
Galcanezumab[22]	Emgality	mab	humanized	calcitonin	Y	migraine
Galiximab		mab	chimeric	CD80		B-cell lymphoma
Gancotamab		scFv	human	HER2/neu		cancer
Ganitumab		mab	human	IGF-1 receptor (CD221)		cancer
Gantenerumab[25]		mab	human	beta amyloid		Alzheimer's disease
Gatipotuzumab[16]		mab	humanized	MUC1		cancer
Gavilimomab[37]		mab	mouse	CD147 (basigin)		graft versus host disease
Gedivumab[16]		mab	human	hemagglutinin HA		?
Gemtuzumab ozogamicin	Mylotarg	mab	humanized	CD33	Y	acute myelogenous leukemia
Gevokizumab		mab	humanized	IL-1β		diabetes etc.
Gilvetmab[16]		mab	veterinary	PCDC1		?
Gimsilumab[6]		mab	human	CSF2		Rheumatoid arthritis
Girentuximab[29]	Rencarex	mab	chimeric	carbonic anhydrase 9 (CA-IX)		clear cell renal cell carcinoma[45]
Glembatumumab vedotin[46][47]		mab	human	GPNMB		melanoma, breast cancer
Golimumab[38]	Simponi	mab	human	TNF-α	Y	Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab		mab	chimeric	CD23 (IgE receptor)		allergic asthma
Gosuranemab		mab	humanized	tau protein		progressive supranuclear palsy
Guselkumab	Tremfya	mab	human	IL23	Y	psoriasis
Ianalumab[6]		mab	human	BAFF-R		autoimmune hepatitis
Ibalizumab[25]	Trogarzo	mab	humanized	CD4	Y	HIV infection
IBI308		?	human	PD-1		squamous cell non-small cell lung cancer
Ibritumomab tiuxetan	Zevalin	mab	mouse	CD20	Y	non-Hodgkin's lymphoma
Icrucumab		mab	human	VEGFR-1		cancer etc.
Idarucizumab[3]	Praxbind	mab	humanized	dabigatran	Y	reversal of anticoagulant effects of dabigatran
Ifabotuzumab[12]		mab	humanized	EPHA3		glioblastoma multiforme[48]
Igovomab	Indimacis-125	F(ab')₂	mouse	CA-125		ovarian cancer (diagnosis)
Iladatuzumab vedotin[6]		mab	humanized	CD97B		cancer
IMAB362		mab	human	CLDN18.2		gastrointestinal adenocarcinomas and pancreatic tumor
Imalumab[18]		mab	human	MIF		cancer
Imaprelimab[4]		mab	humanized	MCAM		?
Imciromab	Myoscint	mab	mouse	cardiac myosin	Y	cardiac imaging
Imgatuzumab[33]		mab	humanized	EGFR		cancer
Inclacumab[26]		mab	human	selectin P		cardiovascular disease
Indatuximab ravtansine[23]		mab	chimeric	SDC1		cancer
Indusatumab vedotin[14]		mab	human	GUCY2C		cancer
Inebilizumab[7]		mab	humanized	CD19		cancer, systemic sclerosis, multiple sclerosis
Infliximab	Remicade	mab	chimeric	TNF-α	Y	Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[49][50]		mab	human	CD51		solid tumors (prostate cancer, melanoma)
Inolimomab		mab	mouse	CD25 (α chain of IL-2 receptor)		graft versus host disease
Inotuzumab ozogamicin[19]	Besponsa	mab	humanized	CD22	Y	ALL
Ipilimumab[30]	Yervoy	mab	human	CD152	Y	melanoma
Iomab-B		?	mouse	CD45		ablation of bone marrow
Iratumumab[30]		mab	human	CD30 (TNFRSF8)		Hodgkin's lymphoma
Isatuximab		mab	chimeric	CD38		multiple myeloma
Iscalimab[4]		mab	human	CD40		?
Istiratumab[6]		mab	human	IGF1R, CD221		advanced solid tumors
Itolizumab[44]	Alzumab	mab	humanized	CD6	Y	psoriasis
Ixekizumab	Taltz	mab	humanized	IL 17A	Y	autoimmune diseases
Keliximab		mab	chimeric	CD4		chronic asthma
Labetuzumab[34]	CEA-Cide	mab	humanized	CEA		colorectal cancer
Lacnotuzumab[16]		mab	humanized	CSF1, MCSF		cancer
Ladiratuzumab vedotin[6]		mab	humanized	LIV-1		cancer
Lampalizumab[33]		Fab	humanized	CFD		geographic atrophy secondary to age-related macular degeneration
Lanadelumab[22]	Takhzyro	mab	human	kallikrein	Y	angioedema
Landogrozumab[7]		mab	humanized	GDF-8		muscle wasting disorders
Laprituximab emtansine[22]		mab	chimeric	EGFR		?
Larcaviximab[16]		mab	chimeric	ebolavirus glycoprotein		Ebola virus
Lebrikizumab		mab	humanized	IL-13		asthma
Lemalesomab[37]		mab	mouse	NCA-90 (granulocyte antigen)		diagnostic agent
Lendalizumab[22]		mab	humanized	C5		?
Lenvervimab[4]		mab	humanized	hepatitis B surfage antigen		hepatitis B
Lenzilumab[18]		mab	human	CSF2		chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia
Lerdelimumab[9]		mab	human	TGF beta 2		reduction of scarring after glaucoma surgery
Leronlimab[4]		mab	humanized	CCR5		breast cancer, HIV
Lesofavumab[16]		mab	human	hemagglutinin HA		?
Letolizumab[16]		scFv	humanized	TRAP		inflammatory diseases
Lexatumumab[2]		mab	human	TRAIL-R2		cancer
Libivirumab[38]		mab	human	hepatitis B surface antigen		hepatitis B
Lifastuzumab vedotin		mab	humanized	phosphate-sodium co-transporter		cancer
Ligelizumab[33]		mab	humanized	IGHE		severe asthma and chronic spontaneous urticaria
Loncastuximab tesirine[6]		mab	chimeric	CD19		cancer
Losatuxizumab vedotin[16]		mab	chimeric/humanized	EGRF, ERBB1 HER1		cancer
Lilotomab satetraxetan[14]		mab	mouse	CD37		cancer
Lintuzumab		mab	humanized	CD33		cancer
Lirilumab[33]		mab	human	KIR2D		solid and hematological cancers
Lodelcizumab[20]		mab	humanized	PCSK9		hypercholesterolemia
Lokivetmab[14]	Cytopoint[51]	mab	veterinary	Canis lupus familiaris IL31	Y	clinical signs of atopic dermatitis in dogs[51]
Lorvotuzumab mertansine		mab	humanized	CD56		cancer
Lucatumumab[8]		mab	human	CD40		multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol		mab	humanized	CD28		autoimmune diseases
Lumiliximab[5]		mab	chimeric	CD23 (IgE receptor)		chronic lymphocytic leukemia
Lumretuzumab[18]		mab	humanized	ERBB3 (HER3)		cancer
Lupartumab amadotin[12]		mab	human	LYPD3		?
Lutikizumab[12]		mab	humanized	interleukin 1 alpha		?
Mapatumumab[17]		mab	human	TRAIL-R1		cancer
Margetuximab		mab	humanized	HER2		breast cancer
Marstacimab		mab	human	TFPI		bleeding with hemophilia
Maslimomab		?	mouse	T-cell receptor
Mavrilimumab		mab	human	GMCSF receptor α-chain		rheumatoid arthritis
Matuzumab[13]		mab	humanized	EGFR		colorectal, lung and stomach cancer
Mepolizumab	Bosatria	mab	humanized	IL-5	Y	asthma and white blood cell diseases
Metelimumab[39]		mab	human	TGF beta 1		systemic scleroderma
Milatuzumab[8]		mab	humanized	CD74		multiple myeloma and other hematological malignancies
Minretumomab		mab	mouse	TAG-72		tumor detection (and therapy?)
Mirikizumab[6]		mab	humanized	IL23A		psoriasis
Mirvetuximab soravtansine		mab	chimeric	folate receptor alpha		ovarian cancer
Mitumomab		mab	mouse	GD3 ganglioside		small cell lung carcinoma
Modotuximab		mab	chimeric	EGFR extracellular domain III		cancer
Mogamulizumab	Poteligeo	mab	humanized	CCR4	Y	adult T-cell leukemia/lymphoma
Monalizumab[7]		mab	humanized	NKG2A		Rheumatoid arthritis, gynecologic malignancies, and other cancers
Morolimumab		mab	human	Rhesus factor
Mosunetuzumab[6]		mab	humanized	CD3E, MS4A1, CD20		cancer
Motavizumab[2]	Numax	mab	humanized	respiratory syncytial virus		respiratory syncytial virus (prevention)
Moxetumomab pasudotox	Lumoxiti	mab	mouse	CD22	Y	hairy cell leukemia
Muromonab-CD3	Orthoclone OKT3	mab	mouse	CD3		prevention of organ transplant rejections
Nacolomab tafenatox		Fab	mouse	C242 antigen		colorectal cancer
Namilumab[15]		mab	human	CSF2
Naptumomab estafenatox[52]		Fab	mouse	5T4		non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine[22]		mab	chimeric	CD37
Narnatumab		mab	human	MST1R (aka RON)		cancer
Natalizumab	Tysabri	mab	humanized	integrin α₄	Y	multiple sclerosis, Crohn's disease
Navicixizumab[22]		mab	chimeric/humanized	DLL4 and VEGFA		cancer
Navivumab[7]		mab	human	influenza A virus hemagglutinin HA
Naxitamab		?	humanized	c-Met		high-risk neuroblastoma and refractory osteomedullary disease
Nebacumab		mab	human	endotoxin		sepsis
Necitumumab[53]	Portrazza	mab	human	EGFR	Y	non-small cell lung carcinoma
Nemolizumab[14]		mab	humanized	IL31RA		eczema[54]
NEOD001		?	humanized	amyloid		primary systemic amyloidosis
Nerelimomab		mab	mouse	TNF-α		?
Nesvacumab		mab	human	angiopoietin 2		cancer
Netakimab[4]	Efleira	mab	chimeric	interleukin 17A		plaque psoriasis
Nimotuzumab[30][55]	Theracim, Theraloc	mab	humanized	EGFR	Y	squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nirsevimab		mab	human	RSVFR		respiratory syncytial virus
Nivolumab	Opdivo	mab	human	PD-1	Y	cancer
Nofetumomab merpentan	Verluma	Fab	mouse	?		cancer (diagnosis)
Obiltoxaximab	Anthim	mab	chimeric	Bacillus anthracis anthrax	Y	Bacillus anthracis spores
Obinutuzumab	Gazyva	mab	humanized	CD20	Y	Chronic lymphatic leukemia
Ocaratuzumab		mab	humanized	CD20		cancer
Ocrelizumab[30]	Ocrevus	mab	humanized	CD20	Y	Rheumatoid arthritis, lupus erythematosus etc.
Odulimomab		mab	mouse	LFA-1 (CD11a)		prevention of organ transplant rejections, immunological diseases
Ofatumumab[17]	Arzerra	mab	human	CD20	Y	chronic lymphocytic leukemia etc.
Olaratumab	Lartruvo	mab	human	PDGF-R α	Y	cancer
Oleclumab[16]		mab	human	5'-nucleotidase		pancreatic and colorectal cancer
Olendalizumab		mab	humanized	complement C5a		systemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease
Olokizumab[44]		mab	humanized	IL6		Rheumatoid arthritis
Omalizumab[37]	Xolair	mab	humanized	IgE Fc region	Y	allergic asthma
Omburtamab[32]		mab	mouse	CD276		cancer
OMS721		?	human	MASP-2		atypical hemolytic uremic syndrome
Onartuzumab		Fab	humanized	human scatter factor receptor kinase		cancer
Ontuxizumab		mab	chimeric/humanized	TEM1		cancer
Onvatilimab[4]		mab	human	VSIR		?
Opicinumab		mab	human	LINGO-1		multiple sclerosis
Oportuzumab monatox[53]	Vicinium	scFv	humanized	EpCAM		bladder cancer
Oregovomab[39]	OvaRex	mab	mouse	CA-125		ovarian cancer
Orticumab[33]		mab	human	oxLDL
Otelixizumab[8]		mab	chimeric/humanized	CD3		diabetes mellitus type 1
Otilimab		mab	human	GMCSF		osteoarthritis, Rheumatoid arthritis
Otlertuzumab		mab	humanized	CD37		cancer
Oxelumab		mab	human	OX-40		asthma
Ozanezumab		mab	humanized	NOGO-A		ALS and multiple sclerosis
Ozoralizumab		mab	humanized	TNF-α		inflammation
Pagibaximab[17]		mab	chimeric	lipoteichoic acid		sepsis (Staphylococcus)
Palivizumab	Synagis, Abbosynagis	mab	humanized	F protein of respiratory syncytial virus	Y	respiratory syncytial virus (prevention)
Pamrevlumab[7]		mab	human	CTGF		idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab[38]	Vectibix	mab	human	EGFR	Y	colorectal cancer
Pankomab		mab	humanized	tumor specific glycosylation of MUC1		ovarian cancer
Panobacumab[53]		mab	human	Pseudomonas aeruginosa		Pseudomonas aeruginosa infection
Parsatuzumab[33]		mab	human	EGFL7		cancer
Pascolizumab[11]		mab	humanized	IL-4		asthma
Pasotuxizumab[18]		mab	chimeric/humanized	folate hydrolase		cancer
Pateclizumab[23]		mab	humanized	LTA		TNF
Patritumab[26]		mab	human	ERBB3 (HER3)		cancer
PDR001		?	humanized	PD-1		melanoma
Pembrolizumab	Keytruda	mab	humanized	PD-1	Y	melanoma and other cancers
Pemtumomab	Theragyn	?	mouse	MUC1		cancer
Perakizumab[33]		mab	humanized	IL 17A		arthritis
Pertuzumab	Perjeta	mab	humanized	HER2/neu	Y	cancer
Pexelizumab[34]		scFv	humanized	C5		reduction of side effects of cardiac surgery
Pidilizumab		mab	humanized	PD-1		cancer and infectious diseases
Pinatuzumab vedotin[20]		mab	humanized	CD22		cancer
Pintumomab		mab	mouse	adenocarcinoma antigen		adenocarcinoma (imaging)
Placulumab		mab	human	human TNF		pain and inflammatory diseases
Plozalizumab[7]		mab	humanized	CCR2		diabetic nephropathy and arteriovenous graft patency
Pogalizumab[22]		mab	humanized	TNFR superfamily member 4		?
Polatuzumab vedotin[20]	Polivy	mab	humanized	CD79B	Y	diffuse large B-cell lymphoma
Ponezumab		mab	humanized	human beta-amyloid		Alzheimer's disease
Porgaviximab[16]		mab	chimeric	Zaire ebolavirus glycoprotein		Ebola virus disease
Prasinezumab[6]		mab	humanized	NACP		Parkinson's disease
Prezalizumab[22]		mab	humanized	ICOSL		?
Priliximab		mab	chimeric	CD4		Crohn's disease, multiple sclerosis
Pritoxaximab[20]		mab	chimeric	E. coli shiga toxin type-1		?
Pritumumab		mab	human	vimentin		brain cancer
PRO 140		?	humanized	CCR5		HIV infection
Quilizumab[26]		mab	humanized	IGHE		asthma
Racotumomab[53]	Vaxira	mab	mouse	NGNA ganglioside	Y	non-small cell lung cancer
Radretumab[15]		mab	human	fibronectin extra domain-B		cancer
Rafivirumab[27]		mab	human	rabies virus glycoprotein		rabies (prophylaxis)
Ralpancizumab		mab	humanized	neural apoptosis-regulated proteinase 1		dyslipidemia
Ramucirumab	Cyramza	mab	human	VEGFR2	Y	solid tumors
Ranevetmab		mab	veterinary	NGF		osteoarthritis in dogs
Ranibizumab[5]	Lucentis	Fab	humanized	VEGF-A	Y	macular degeneration (wet form)
Raxibacumab[19]		mab	human	anthrax toxin, protective antigen	Y	anthrax (prophylaxis and treatment)
Ravagalimab[4]		mab	humanized	CD40		Crohn's disease
Ravulizumab[6]	Ultomiris	mab	humanized	C5	Y	paroxysmal nocturnal hemaglobinuria, atypical hemolytic uremic syndrome
Refanezumab		mab	humanized	myelin-associated glycoprotein		recovery of motor function after stroke
Regavirumab		mab	human	cytomegalovirus glycoprotein B		cytomegalovirus infection
REGN-EB3		mab	human			3 mabs for ebola infection with FDA orphan drug status
Relatlimab		mab	human	LAG3		melanoma
Remtolumab[12]		mab	human	interleukin 17 alpha, TNF		?
Reslizumab[34]	Cinqair	mab	humanized	IL-5	Y	inflammations of the airways, skin and gastrointestinal tract
Rilotumumab		mab	human	HGF		solid tumors
Rinucumab		mab	human	platelet-derived growth factor receptor beta		neovascular age-related macular degeneration
Risankizumab[7]	Skyrizi	mab	humanized	IL23A	Y	Crohn's disease, psoriasis, psoriatic arthritis, and asthma
Rituximab	MabThera, Rituxan	mab	chimeric	CD20	Y	lymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol[7]		mab	humanized	Pseudomonas aeruginosa type III secretion system		?
Robatumumab		mab	human	IGF-1 receptor (CD221)		cancer
Rmab	RabiShield	?	human	rabies virus G glycoprotein	Y	post-exposure prophylaxis of rabies
Roledumab[44]		mab	human	RHD		Rh disease
Romilkimab[4]		mab	chimeric/humanized	interleukin 13		?
Romosozumab	Evenity	mab	humanized	sclerostin	Y	osteoporosis
Rontalizumab		mab	humanized	IFN-α		systemic lupus erythematosus
Rosmantuzumab		mab	humanized	root plate-specific spondin 3		cancer
Rovalpituzumab tesirine[7]		mab	humanized	DLL3		small cell lung cancer
Rovelizumab	LeukArrest	mab	humanized	CD11, CD18	Y	haemorrhagic shock etc.
Rozanolixizumab[12]		mab	chimeric/humanized	FCGRT		PTI, myasthenia gravis
Ruplizumab[9]	Antova	mab	humanized	CD154 (CD40L)	Y	rheumatic diseases
SA237		?	humanized	IL-6R		neuromyelitis optica and neuromyelitis optica spectrum disorders
Sacituzumab govitecan		mab	humanized	TROP-2		triple-negative breast cancer
Samalizumab		mab	humanized	CD200		cancer
Samrotamab vedotin[4]		mab	chimeric/humanized	LRRC15		cancer
Sarilumab	Kevzara	mab	human	IL6	Y	Rheumatoid arthritis, ankylosing spondylitis
Satralizumab		mab	humanized	IL6 receptor		neuromyelitis optica
Satumomab pendetide		mab	mouse	TAG-72		cancer (diagnosis)
Secukinumab	Cosentyx	mab	human	IL 17A	Y	uveitis, Rheumatoid arthritis psoriasis
Selicrelumab[16]		mab	human	CD40		?
Seribantumab[20]		mab	human	ERBB3 (HER3)		cancer
Setoxaximab[20]		mab	chimeric	E. coli shiga toxin type-2		?
Setrusumab[6]		mab	human	SOST		?
Sevirumab		?	human	cytomegalovirus		cytomegalovirus infection
Sibrotuzumab		mab	humanized	FAP		cancer
SGN-CD19A		mab	humanized	CD19		acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SHP647		?	human	mucosal addressin cell adhesion molecule		Crohn's disease
Sifalimumab		mab	humanized	IFN-α		SLE, dermatomyositis, polymyositis
Siltuximab	Sylvant	mab	chimeric	IL-6	Y	cancer
Simtuzumab[33]		mab	humanized	LOXL2		fibrosis
Siplizumab[11]		mab	humanized	CD2		psoriasis, graft-versus-host disease (prevention)
Sirtratumab vedotin[6]		mab	human	SLITRK6		cancer
Sirukumab		mab	human	IL-6		Rheumatoid arthritis
Sofituzumab vedotin		mab	humanized	CA-125		ovarian cancer
Solanezumab[53]		mab	humanized	beta amyloid		Alzheimer's disease
Solitomab[26]		BiTE	mouse	EpCAM		gastrointestinal, lung, and other cancers
Sonepcizumab[56]		?	humanized	sphingosine-1-phosphate		choroidal and retinal neovascularization
Sontuzumab[55]		mab	humanized	episialin
Spartalizumab[6]		mab	humanized	PDCD1, CD279		melanoma
Stamulumab[30][55]		mab	human	myostatin		muscular dystrophy
Sulesomab	LeukoScan	Fab'	mouse	NCA-90 (granulocyte antigen)		osteomyelitis (imaging)
Suptavumab		mab	human	RSVFR		medically attended lower respiratory disease
Sutimlimab[4]		mab	chimeric/humanized	C1s		cold agglutinin disease
Suvizumab[46]		mab	humanized	HIV-1		viral infections
Suvratoxumab[16]		mab	human	Staphylococcus aureus alpha toxin		nosocomial pneumonia
Tabalumab		mab	human	BAFF		B-cell cancers
Tacatuzumab tetraxetan	AFP-Cide	mab	humanized	alpha-fetoprotein		cancer
Tadocizumab[55]		Fab	humanized	integrin α_IIbβ₃		percutaneous coronary intervention
Talacotuzumab[6]		mab	humanized	CD123		leukemia etc.
Talizumab		mab	humanized	IgE		allergic reaction
Tamtuvetmab[22]	Tactress	mab	veterinary	CD52
Tanezumab[27]		mab	humanized	NGF		pain
Taplitumomab paptox[37]		mab	mouse	CD19		cancer
Tarextumab		mab	human	Notch receptor		cancer
Tavolimab		mab	chimeric/humanized	CD134		cancer
Tefibazumab[19]	Aurexis	mab	humanized	clumping factor A		Staphylococcus aureus infection
Telimomab aritox		Fab	mouse	?
Telisotuzumab vedotin		mab	humanized	HGFR		cancer
Tenatumomab[8]		mab	mouse	tenascin C		cancer
Teneliximab[11]		mab	chimeric	CD40		autoimmune diseases and prevention of organ transplant rejection
Teplizumab[25]		mab	humanized	CD3		diabetes mellitus type 1
Tepoditamab[4]		mab	human	dendritic cell-associated lectin 2		cancer
Teprotumumab		mab	human	IGF-1 receptor (CD221)		thyroid eye disease
Tesidolumab[14]		mab	human	C5
Tetulomab		mab	humanized	CD37		cancer[57]
Tezepelumab[7]		mab	human	TSLP		asthma, atopic dermatitis
TGN1412		?	humanized	CD28		chronic lymphocytic leukemia, Rheumatoid arthritis
Tibulizumab[6]		mab	humanized	BAFF		autoimmune disorders
Tildrakizumab	Ilumya	mab	humanized	IL23	Y	immunologically mediated inflammatory disorders
Tigatuzumab[8]		mab	humanized	TRAIL-R2		cancer
Timigutuzumab[16]		mab	humanized	HER2		cancer
Timolumab[22]		mab	human	AOC3
Tiragotumab[6]		mab	human	TIGIT		cancer
Tislelizumab[6]		mab	humanized	PCDC1, CD279		non-small cell lung cancer
Tisotumab vedotin[7]		mab	human	coagulation factor III		relapsed or refractory cervical cancer[58]
TNX-650		?	humanized	IL-13		Hodgkin's lymphoma
Tocilizumab[5]	Actemra, RoActemra	mab	humanized	IL-6 receptor	Y	Rheumatoid arthritis
Tomuzotuximab[16]		mab	humanized	EGFR, HER1		cancer
Toralizumab[11]		mab	humanized	CD154 (CD40L)		Rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[3]		mab	human	Staphylococcus aureus
Tositumomab	Bexxar	?	mouse	CD20	Y	follicular lymphoma
Tovetumab		mab	human	PDGFRA		cancer
Tralokinumab		mab	human	IL-13		asthma, atopic dermatitis
Trastuzumab	Herceptin	mab	humanized	HER2/neu	Y	breast cancer
Trastuzumab emtansine	Kadcyla	mab	humanized	HER2/neu	Y	breast cancer
TRBS07[59]	Ektomab	3funct	?	GD2 ganglioside		melanoma
Tregalizumab[15]		mab	humanized	CD4
Tremelimumab		mab	human	CTLA-4		non-small cell lung, head & neck, urothelial cancer
Trevogrumab		mab	human	growth differentiation factor 8		muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[30][55]		mab	humanized	EpCAM		cancer
Tuvirumab		?	human	hepatitis B virus		chronic hepatitis B
Ublituximab[15]		mab	chimeric	MS4A1		multiple sclerosis, chronic lymphocytic leukemia
Ulocuplumab		mab	human	CXCR4 (CD184)		hematologic malignancies
Urelumab		mab	human	4-1BB (CD137)		cancer etc.
Urtoxazumab[5]		mab	humanized	Escherichia coli		diarrhoea caused by E. coli
Ustekinumab[27]	Stelara	mab	human	IL-12, IL-23	Y	multiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab[24]		mab	human	4-1BB (CD137)		diffuse large B-cell lymphoma
Vadastuximab talirine[7]		mab	chimeric	CD33		Acute myeloid leukemia
Vanalimab[4]		mab	humanized	CD40		?
Vandortuzumab vedotin[14]		mab	humanized	STEAP1		cancer
Vantictumab		mab	human	Frizzled receptor		cancer
Vanucizumab[18]		mab	humanized	angiopoietin 2		cancer
Vapaliximab[11]		mab	chimeric	AOC3 (VAP-1)
Varisacumab[16]		mab	human	VEGF-A		angiogenesis
Varlilumab		mab	human	CD27		solid tumors and hematologic malignancies
Vatelizumab[23]		mab	humanized	ITGA2 (CD49b)
Vedolizumab	Entyvio	mab	humanized	integrin α₄β₇	Y	Crohn's disease, ulcerative colitis
Veltuzumab[8]		mab	humanized	CD20		non-Hodgkin's lymphoma
Vepalimomab		mab	mouse	AOC3 (VAP-1)		inflammation
Vesencumab[15]		mab	human	NRP1		solid malignancies
Visilizumab[37]	Nuvion	mab	humanized	CD3		Crohn's disease, ulcerative colitis
Vobarilizumab[22]		scFv	humanized	IL6R		inflammatory autoimmune diseases
Volociximab[17]		mab	chimeric	integrin α₅β₁		solid tumors
Vonlerolizumab		mab	humanized	CD134		cancer
Vopratelimab[4]		mab	humanized	CD278, aka ICOS		?
Vorsetuzumab mafodotin		mab	humanized	CD70		cancer
Votumumab	HumaSPECT	mab	human	tumor antigen CTAA16.88		colorectal tumors
Vunakizumab[12]		mab	humanized	interleukin 17 alpha		?
Xentuzumab[22]		mab	humanized	IGF1, IGF2		?
XMAB-5574		?	humanized	CD19		diffuse large B-cell lymphoma
Zalutumumab[17]	HuMax-EGFr	mab	human	EGFR		squamous cell carcinoma of the head and neck
Zanolimumab[5]	HuMax-CD4	mab	human	CD4		Rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[33]		mab	chimeric	HER1		cancer
Zenocutuzumab[6]		mab	humanized	ERBB3, HER3		cancer
Ziralimumab[37]		mab	human	CD147 (basigin)		?
Zolbetuximab[6] (=IMAB362, Claudiximab)		mab	chimeric	Claudin 18 Isoform 2		gastric cancer, gastrointestinal adenocarcinoma and pancreatic cancer
Zolimomab aritox		mab	mouse	CD5		systemic lupus erythematosus, graft-versus-host disease

References

"United Therapeutics 10-K report". Retrieved 5 November 2011.
World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information. 20 (2).
World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information. 18 (1).
World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4).
World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information. 14 (2).
"Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information. 16 (2).
World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information. 17 (1).
World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information. 19 (2).
World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information. 18 (4).
World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information. 21 (2).
World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information. 22 (2).
"BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009.
World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information. 23 (2).
World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information. 19 (4).
World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information. 5 (4).
World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information. 15 (2).
World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2).
World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information. 18 (1).
World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information. 14 (4).
World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information. 18 (2).
World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information. 16 (12).
Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160.
Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
"Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®".
World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102" (PDF). WHO Drug Information. 23 (4).
NCI Drug Dictionary: Glemtumumab vedotin
"Results from Cure Brain Cancer Foundation-funded trial show promise". www.curebraincancer.org.au. Retrieved 2019-06-14.
Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Retrieved 2018-07-06.
World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information. 20 (4).
World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information.
Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jonathan; Kabashima, Kenji; XCIMA Study Group (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150.
World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information. 20 (3).
Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.
Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research. 33 (1): 85–95. PMID 23267131.
Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Retrieved 22 February 2018.
Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Ch1418-1] "United Therapeutics 10-K report". Retrieved 5 November 2011.

[WHOList95-2] World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information. 20 (2).

[WHOList109-3] World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).

[WHOList118-4] World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).

[WHOList90-5] World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information. 18 (1).

[WHOList117-6] World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).

[WHOList113-7] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).

[WHOList98-8] World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4).

[WHOList83-9] World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information. 14 (2).

[IMA-638-10] "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.

[WHOList87-11] World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information. 16 (2).

[WHORList77-12] World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).

[WHOList88-13] World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information. 17 (1).

[WHOList112-14] World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).

[WHOList104-15] World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).

[WHOList116-16] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).

[WHOList93-17] World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information. 19 (2).

[WHOList111-18] World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).

[WHOList92-19] World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information. 18 (4).

[WHOList108-20] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).

[WHOList110-21] World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).

[WHOList114-22] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).

[WHOList105-23] World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).

[WHOList115-24] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).

[WHOList97-25] World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information. 21 (2).

[WHOList106-26] World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).

[WHOList99-27] World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information. 22 (2).

[ALD518-28] "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009.

[WHOList101-29] World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information. 23 (2).

[WHOList94-30] World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information. 19 (4).

[WHOList66-31] World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information. 5 (4).

[WHOList119-32] World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).

[WHOList107-33] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

[WHOList85-34] World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information. 15 (2).

[WHOList77-35] World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2).

[WHOList51-36] World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information. 18 (1).

[WHOList84-37] World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information. 14 (4).

[WHOList91-38] World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information. 18 (2).

[WHOList86-39] World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information. 16 (12).

[40] Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.

[41] Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160.

[NCT00883896-42] Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov

[NCT00563524-43] Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov

[WHOList103-44] World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.

[45] "Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®".

[WHOList102-46] World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102" (PDF). WHO Drug Information. 23 (4).

[Glembatumumab-47] NCI Drug Dictionary: Glemtumumab vedotin

[48] "Results from Cure Brain Cancer Foundation-funded trial show promise". www.curebraincancer.org.au. Retrieved 2019-06-14.

[NCT00537381-49] Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov

[NCT00246012-50] Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov

[Guthrie_2017-51] Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Retrieved 2018-07-06.

[WHOList96-52] World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information. 20 (4).

[WHOList100-53] World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information.

[54] Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jonathan; Kabashima, Kenji; XCIMA Study Group (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150.

[WHOList56-55] World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information. 20 (3).

[56] Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.

[57] Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research. 33 (1): 85–95. PMID 23267131.

[58] Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Retrieved 22 February 2018.

[59] Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099.

Engineered monoclonal antibodies and antibody mimetics
Whole antibody	bispecific: Trifunctional antibody
Fab fragment	F(ab')₂ fragment / Fab' fragment bispecific: Chemically linked Fab
Variable fragment	Single-chain variable fragment / di-scFv / tri-scFv Single-domain antibody Small modular immunopharmaceutical bispecific: T-cell engager
Smaller units	Microantibody
Intracellular	Intrabody
Antibody mimetics	Affibody molecule Affilin Affimer Affitin Alphabody Anticalin Avimer DARPin Kunitz domain peptide Monobody nanoCLAMP